DOCSLIB.ORG

Ncbiotech Company Directory

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ncbiotech Company Directory NCBiotech Company Directory Many thanks to our sponsors for making this directory possible July 2012 Alston & Bird • BASF • Bayer CropScience Golden LEAF Biomanufacturing Training and Education Center Cannon Research Center • Fujifilm Diosynth Biotechnologies • GlaxoSmithKline NC Community Colleges BioNetwork • Piedmont Triad Research Park Pozen • PPD • Smith Anderson ncbiotech.org/directory ncbiotech.org/directory 2012CoDirectoryCOVER-final_km-5-14-12.indd 2-3 5/14/12 5:02 PM NCBiotech Company Directory 2012 Growing a healthier world, one harvest at a time. Chairman,Our Board task of Directors is simple, yet monumental. To provide enough food for the world, while John L. Atkins,protecting III, FAIA it at the same time. We believe that with the right combination of innovative President andscience, Chief Executivetenacious Officer problem solving and unshakable passion, we can do it. We will meet E. Norris Tolson Science For A Better Life the needs of today while laying a foundation for a better tomorrow. And in doing so, we Senior Vice President, Science andwill Business not only Development grow a healthier world, we will make sure that abundance endures for us all. Kenneth R. Tindall, Ph.D. Learn more at www.BayerCropScience.us. Senior Vice President, Statewide Operations and Economic Development Michael Wilkins REGIONAL OFFICES Vice President, Statewide Operations Steven Casey, MBA Executive Director, Eastern Office Mark Phillips Executive Director, Greater Charlotte Office Cover photos (back and front cover, left to right): NC Research Campus, NCBiotech Center, BASF SE, Executive Director, Piedmont Triad Office NCBiotech Center, UNCW/MARBIONC/Jamie Moncrief, RTI International, East Carolina University, NC Nancy Johnston State University Photo (above) NCBiotech Center Executive Director, Southeastern Office Randall Johnson, MBA NCBiotech Company Directory is produced by Red Hand Media LLC Executive Director, Western Office 5605 77 Center Drive, Suite 101, Charlotte, NC 28217. Telephone 704-523-6987. Fax 704-523-4211. Jonathon Lawrie, Ph.D. Editorial content provided by underwriters. Growing a healthier world, one harvest at a time. Our task is simple, yet monumental. To provide enough food for the world, while protecting it at the same time. We believe that with the right combination of innovative science, tenacious problem solving and unshakable passion, we can do it. We will meet Science For A Better Life the needs of today while laying a foundation for a better tomorrow. And in doing so, we will not only grow a healthier world, we will make sure that abundance endures for us all. Learn more at www.BayerCropScience.us. Bayer CropScience LP, 2 TW Alexander Drive, Research Triangle Park, NC 27709. Always read and follow label instructions. Bayer and the Bayer Cross are registered trademarks of Bayer. For additional product information, call toll-free 1-866-99-BAYER (1-866-992-2937) or visit our Web site at www.BayerCropScience.us. BCS_COM_M2_1097_BizNC_R1.indd Saved at 4-4-2012 3:43 PM Printed At None Client Bayer Crop Science Media Type Magazine DEPARTMENT: Art Director Copywriter Acct. Manager Studio Artist Proofreader Traffic Production Live 7” x 10” Trim 8.125” x 10.875” Bleed 8.375” x 11.125” APPROVAL: Job Title Corp. Bus. NC Ad Pubs Business or North Carolina Addl. Notes: None Ad Code None Bayer_redo.5H.indd 1 4/27/12 3:03:37 PM Bayer CropScience LP, 2 TW Alexander Drive, Research Triangle Park, NC 27709. Always read and follow label instructions. Bayer and the Bayer Cross are registered trademarks of Bayer. For additional product information, call toll-free 1-866-99-BAYER (1-866-992-2937) or visit our Web site at www.BayerCropScience.us. BCS_COM_M2_1097_BizNC_R1.indd Saved at 4-4-2012 3:43 PM Printed At None Client Bayer Crop Science Media Type Magazine DEPARTMENT: Art Director Copywriter Acct. Manager Studio Artist Proofreader Traffic Production Live 7” x 10” Trim 8.125” x 10.875” Bleed 8.375” x 11.125” APPROVAL: Job Title Corp. Bus. NC Ad Pubs Business or North Carolina Addl. Notes: None Ad Code None NCBiotech’s Regional Offices 77 Research Winston-Salem Triangle 95 85 Piedmont RTP 40 Eastern Triad 40 Greater 85 Raleigh Asheville Charlotte Greenville 26 77 Western 95 Charlotte Southeastern Advantage North Carolina 40 North Carolina’s 500+ companies enjoy outstanding quality of Wilmington life in addition to: • Workforce Training • Collaborative Community • Low Business Costs Top Regional Biotechnology Assets EASTERN PIEDMONT TRIAD SOUTHEASTERN Regional Office: Greenville Regional Office: Winston-Salem Regional Office: Wilmington Phone: 252-328-9981 Phone: 252-725-6672 Phone: 910-763-5747 Sector Strengths: Sector Strengths: Sector Strengths: • Ag Biotech • Regenerative Medicine • Marine Biotech • Functional Biofuels • Nanobiotechnology • Contract Research • Marine Biotech • Medical Devices • Pharmaceuticals and Nutraceuticals ncbiotech.org/east ncbiotech.org/triad ncbiotech.org/southeast Greater CHarlotte ResearcH TRIANGLE PARK WESTERN Regional Office: Charlotte Headquarters: Research Triangle Park Regional Office: Asheville Phone: 704-687-8563 Phone: 919-541-9366 Phone: 828-290-1431 Sector Strengths: Sector Strengths: Sector Strengths: • Bioinformatics • Biomanufacturing • Medical Devices • Health and Nutrition • Contract Research • Natural Products • Ag Biotech • Fermentation • Biomedical Technologies ncbiotech.org/west ncbiotech.org/charlotte ncbiotech.org North Carolina Companies 1 Companies 1 – Al Advanced Animal Diagnostics Inc. (Morrisville) develops diagnostics to detect and manage disease states, reproductive, nutritional and overall health status of production animals. AAD’s first product is a diagnostic test for mastitis in dairy cows. www.advancedanimaldiagnostics.com Advanced Liquid Logic Inc. (RTP) uses digital microfluidics to develop molecular diagnostics, bioassays and life-science research tools. www.liquid-logic.com Aerial Biopharma LLC (Morrisville) develops biologic and small-molecule central nervous system therapeutics, including treatments for narcolepsy and chronic pain. www.aerialbio.com Aerie Pharmaceuticals Inc. (RTP) researches and develops treatments for glaucoma. www.aeriepharma.com Affinergy Inc. (RTP) uses biotechnology GRIFOLS methods to create application-specific coatings for orthopedic and cardiovascular 13C Molecular Inc. (Fayetteville) provides Actavis US (Lincolnton) manufactures OTC medical devices. stable-isotope labeled, custom synthesized and prescription hydrocortisone, anti-fungal www.affinergy.com organic compounds to the pharmaceutical and permethrin products as creams, and biomedical industries. ointments, liquids and suppositories. Agile Sciences Inc. (Raleigh) identifies small www.13cmolecular.com www.actavis.us molecules that inhibit and disperse bacterial biofilms. The company investigates AAIPharma Services Corp. (Wilmington and Adherex Technologies Inc. (RTP) applications in medicine, agriculture and Durham) provides drug product development develops cancer therapeutics. Its lead industry. services such as formulation development, product under development is Eniluracil, www.agilesci.com analytical chemistry and manufacturing. The an oral dihydropyrimidine dehydrogenase company’s solid-dose manufacturing facility inhibitor to improve the tolerability and Ajinomoto North America (Raleigh) provides clinical and commercial supplies on effectiveness of oncology drugs. manufactures pharmaceutical-grade amino contract. www.adherex.com acids and custom-blended amino acid www.aaipharma.com mixtures. Adroit Pharmaceutical Development LLC www.ajiaminoscience.com AccuGenomics Inc. (Wilmington) develops (Durham) identifies new and improved gene expression tests to diagnose and formulations and process technologies. Alaeras Inc. (Cary) designs and manufactures monitor cancer treatment. Its primary focus is on inhalation and drug-delivery products. The company www.accugenomics.com dermatological product development. develops a platform technology for dry- www.adroitpharmdev.com powder nasal vaccines that do not require Ace Bio-PharmTech LLC (High Point) uses refrigeration. asymmetric synthesis technologies to ADS Pharma Consulting LLC (Cary) www.alaeras.com develop R&D processes, formulations of provides drug development services, branded and generic pharmaceuticals and including Active Pharmaceutical Ingredient Aldagen Inc. (Durham) develops adult active pharmaceutical ingredients. route development and manufacture, stem cell products for tissue repair and www.acebiopharm.com analytical, pre- and formulation development, regeneration. clinical batch manufacture and chemistry, www.aldagen.com manufacturing and controls regulatory affairs. www.adspharma.net 2 North Carolina Companies Companies Al – Ar Alderon BioSciences Inc. (Newport) AlphaVax Inc. (RTP) develops vaccine Applied Catheter Technologies Inc. develops point-of-care diagnostics. technology with applications in infectious (Winston-Salem) develops drug-coated disease, cancer and biodefense threats. catheters for male urethral stricture and Alera Labs LLC (RTP) provides contract www.alphavax.com abdominal adhesions. research, molecular microbiology and www.appliedcatheter.com analytical chemistry laboratory services Alte Biosciences Inc. (Cary) develops to small and mid-size pharmaceutical and therapeutics targeting irritable bowel disease, Applied Micro Products Inc. (Chapel Hill) medical device companies. rheumatoid arthritis and related disorders. manufactures wood preservation products www.aleralabs.com
Load more

Recommended publications
  • Life Science District
    Fitzsimons Life Science District a great place to raise an idea Located in Aurora, Colorado, it’s one of the largest bioscience developments in the country, a place where there’s plenty of room to grow an idea from discovery to market viability. Whether you start in the bioscience incubator or move into a state-of-the art lab facility, everything you need is close at hand. A cluster of talent and resources is available to you, including direct access to the more than 80 core laboratories at the University of Colorado Anschutz Medical Campus – all just steps away. Features throughout the district, such as parks and conference facilities, are designed to inspire collaboration. And a nearby mix of shops, restaurants and homes let your people thrive right along with your ideas. For leasing and land purchase opportunities at the Colorado Science + Technology Park, within the Fitzsimons Life Science District, call 720-941-7100. Join the conversation at FitzScience.com FIT 110352 Brand Ad_M.indd 1 3/23/11 1:32 PM Improve the health of your business. Collaborations between bioscience 227 acres of state-of-the-art patient successful Colorado companies such companies and faculty researchers at care, research and education, the as Myogen/ Gilead Sciences Colorado, the University of Colorado Anschutz Anschutz Medical Campus provides GlobeImmune, ARCA, and ApopLogic Medical Campus are flourishing. unique opportunities for business Pharmaceuticals. And with Denver Which means the opportunities for development. The University’s International Airport being only 15 improvement—in the health of Technology Transfer o ce, ranked minutes away, access to both coasts Coloradoans and in the health of among the top 20 universities for takes only a few hours.
    [Show full text]
  • ЗМШИ ВНЕСЕНО Наказ Y1ihicerepctba Охорони Здоров'я Укратни
    ЗАТВЕРДЖЕНО Наказ MiHic•cpcTBa охорони здоров'я УкраТни ЗМШИ ВНЕСЕНО Наказ Y1iHicerepcTBa охорони здоров'я УкраТни 1 Н СТРУКЦIЯ для медичного застосування засобу БЮВЕН (BIOVEN) СктаД: ДЈючаречовина: Нитап normal immunoglobulin for intravenous administration; мл препарату активноТ 6iJIk0B0T G —(),l г; Допомјжнј речовини: (кислота вода для форма. Розчин для ОсновнЈ властивостј.• прозора або з незначното опалесцен[јею, безбарвна або злегка жовтуватого кольору Фармакотерапевтична трупа. людини нормальний для введення. код АТХ Ј06В А02. властивостј. Препарат е активною G у IgGl: 52 %, lgG2: 32 %, IgG3: 7 %, IgG4: 4 %), граничний BMiCT А у становить 400 мкг/мл. компонентом препарату е що akTIIBHicT10проти захворювань —BipyciB i у т.ч. гепатиту А i В, Bipycy герпеса людини 1 типу, 2 типу та 6 типу, Bipycy Епштейна-Барр, грипу, кору, паротиту, краснухи, коклюшу, кишковоТ налички, пневмокока, правцевого та токсину. Мас також що проявлясгься у Препарат низькою спонтанною антикомплементарною Препарат с нативним О, BCi комплементу, ефекторну та опсоно-фагоцитарну Препаратс активною 6iJIk0B010 що з сироватки або плазми kPOBi людини, на до BlJl-l, до Bipycy гепатиту С та поверхневого антигену Bipycy гепатиту В, очищеною та концентрованою методом спиртоводними осадниками, яка пройшла BipycH0T сольвент-детергентним методом. про модельних BipyciB у табл. 1. Таблиця BipyciB Результат випробування Bipyc Фактор титру методомПЛР Bi с iM оде людини 5.01 ТСП)ю/см Bi с гепап С 5,51 Bi сп стогоге пес 11-готип 6,01 ТСП)5Ысм Bipyc BipycH0T великоТ рога- 5,5 тот х доби Bi с псевдосказ 10ТСЮ5Ысм Енте Bi с свиней 1-го тип 4,6 1 с людини У-го тип 10ТСП)$Ысм Bi с гепа каченят 1-го тип н/д Bi с вези ля ного стомати 7,01 10 н/д ж/д —немае даних Фарл:акокгнетика.
    [Show full text]
  • 2020 Ncbiotech Company Directory Lists 735 Life Science Companies Across the State
    NCBIOTECH Company Directory 2020 NC’s 35-Year Transformation When civic and business leaders decided in 1984 that North Carolina should take a leadership role in staking an economic future in the life sciences, they started by establishing the North Carolina Biotechnology Center. At the time, there were 32 companies statewide that could be considered part of that sector, employing 3,000 people. Now, after 35 years of continued state investment in the Center, the print version of this 2020 NCBiotech Company Directory lists 735 life science companies across the state. And today they employ 66,000 people in a wide range of excellent jobs that pay, on average, twice the average private-sector wage. Then there are 2,400 more support companies, listed in the online version of this directory. In all, the sector directly or indirectly impacts some 240,000 people statewide. It all adds up to $83.3 billion in annual economic activity for North Carolina, and an influx of $2.2 billion in state and local tax income. Of the 735 companies in this directory, 160 of them are based on technologies developed at North Carolina universities. One of the most successful, started as Quintiles (now IQVIA) in a tiny mobile office on the campus of the University of North Carolina at Chapel Hill, has given birth to the multi-billion-dollar Contract Research and Testing industry. North Carolina remains the epicenter of the field, now home to more than 150 such companies employing 24,250 workers. NCBiotech has been the constant catalyst through all this growth, deploying billions of dollars in research funding to universities across the state, and, through the years, $44 million in loans to 211 entrepreneurial companies.
    [Show full text]
  • Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines: a Randomized
    medRxiv preprint doi: https://doi.org/10.1101/2020.08.18.20177527; this version posted October 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomized, 2 double-blind, non-inferiority trial 3 4 Aitana Juan-Giner, MSc1,*, Derick Kimathi, MBChB2,3*, Kyra H. Grantz, BA4,5,6, Mainga M. 5 Hamaluba, MD2, Patrick Kazooba, MBChB7, Patricia Njuguna, MMed2, Gamou Fall, PhD8, 6 Moussa Dia, MSc8, Ndeye S. Bob, PhD8, Thomas P. Monath, MD9, Alan D. Barrett, PhD10, 7 Joachim Hombach, PhD11, Edgar M. Mulogo, PhD12, Immaculate Ampeire, MBChB13, Henry 2 7 7 8 K. Karanja, MSc , Dan Nyehangane, MSc , Juliet Mwanga-Amumpaire, MMed , Derek A.T. 9 Cummings, PhD4,5, Philip Bejon, Prof2,3, George M. Warimwe, PhD2,3,#, Rebecca F. Grais, 10 PhD1,#. 11 12 1 Epicentre, Paris, France 13 2 Kenya Medical Research Institute – Wellcome Trust Research Programme, Kilifi, Kenya 14 3 Centre for Tropical Medicine & Global Health, University of Oxford, UK 15 4 Department of Biology, University of Florida 16 5 Emerging Pathogens Institute, University of Florida 17 6 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health 18 7 Epicentre Mbarara Research Centre, Uganda 19 8 Institut Pasteur Dakar, Senegal 20 9 Crozet BioPharma LLC, Devens MA, USA 21 10 Sealy Institute for Vaccines Sciences and Department of Pathology, University of Texas 22 Medical Branch, USA 23 11 Immunization, Vaccines & Biologicals, World Health Organization, Geneva, Switzerland 24 12 Department of Community Health, Mbarara University of Science & Technology, Uganda 25 13 Expanded Program on Immunization, Ministry of Health, Uganda 26 27 *Co-first author; #Co-senior author 28 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • Annual Report 2020
    ANNUAL REPORT 2020 Caring for People’s Health as a Trusted Partner 2020 A Year like none before Peter Goldschmidt CEO Dear Investors, dear Partners, 2020 was for each of us a demanding year. Like all of you, we at STADA had to deal with new challenges and to adapt to a new situation in our jobs as well as at home with our family. I would like to express my gratitude to all employees worldwide. You have made an extraordinary contribution to our society through your tireless efforts. We can be proud of the strong crisis resilience STADA has shown despite challeng- ing market conditions during the pandemic. The company has proven itself to be a growth leader and go-to-partner in Consumer Healthcare and Generics, with a rapidly expanding Specialty Pharma presence in areas such as Parkinson’s and biosimilars. I’m particularly gratified by how our diverse global team has come through the crisis true to our Purpose of “Caring for People’s Health as a Trusted Partner”. Across the organization, people have pulled together, even if they have been physically distant; this close collaboration across continents truly embodies our value One STADA. Keep Supplying Medicines We care for people’s health as a trusted partner by being able to keep supplying medicines, even during lockdowns. Our 6,000 production staff did an outstanding job in these difficult times. STADA provides a broad portfolio from supplements that enable people to stay healthy and support their immune systems through to essential treatments for diseases in nearly every therapeutic area, such as cancer, heart, central nervous system, gastrointestinal and pain relief.
    [Show full text]
  • Company Directory
    NCBIOTECH Company Directory ncbiotech.org/directory NC’s Life Science Transformation The 34 years of work by the North Carolina Biotechnology Center has proven to be transformative for the state – especially for its manufacturing workforce. As employment in the state’s furniture, textile and tobacco factories tumbled over the past three decades, the number of people working in pharmaceutical and medicine manufacturing has grown from a few dozen to about 21,000 today. And pharmaceutical manufacturing is just one important segment of North Carolina’s transformational life science community. It doesn’t include the thousands of people in high-tech agriculture, or medical device commercialization, or contract research and development – a life science ecosystem totaling 63,000-plus workers at more than 700 companies statewide. The annual NCBiotech Company Directory print edition aggregates information on these 700+ companies, while the online version includes nearly 2,300 supporting companies such as patent law firms specializing in life science work. They bring the direct and indirect life science workforce total to 260,000. Survey Shows Commuters Statewide What isn’t so obvious is the fact that today there are life That took a lot of teamwork, including some science and/or support companies in 85 of North fabulous support from human resources and Carolina’s 100 counties. Also, even if your county other key people at 58 companies across the state, doesn’t yet have one of these companies, people from mostly life science firms. your county are likely to be working for one. Some of them have a hefty commute, to be sure.
    [Show full text]
  • Matinas Biopharma Holdings, Inc. 10K 2020 V1
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 1545 Route 206 South, Suite 302 Bedminster, New Jersey 07921 (Address of principal executive offices) (Zip Code) 908-443-1860 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, par value $0.0001 MTNB NYSE American Securities registered pursuant to Section 12(g) of the Act: None. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [ ] No [X] Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes [ ] No [X] Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Qualifying Therapeutic Discovery Project Grants
    Qualifying Therapeutic Discovery Project Grants The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant. The project descriptions below were extracted from the applicant certification forms as submitted. Alabama $3,708,304.65 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Molecular Heparan Sulfate Agenta Biotechnologies Delivery in Barrier Membranes $59,614.76 $184,864.48 Inc and Soft Tissue Wound Closure DELIVERY OF GROWTH- AGENTA FACTOR CO-RECEPTOR BIOTECHNOLOGIES HEPARAN SULFATE IN $169,808.39 $6,666.50 INC BONE GRAFT SUBSTITUTES FOR REPAIR BioCryst BCX4208 for Treatment of $244,479.25 Pharmaceuticals Inc Gout BioCryst Peramivir for Treatment of $244,479.25 Pharmaceuticals, Inc Influenza BioCryst Forodesine for Treatment of $244,479.25 Pharmaceuticals, Inc CLL and CTCL BioCryst BCX4161 for Treatment of $86,380.89 Pharmaceuticals, Inc. Hereditary Angioedema JAK Inhibitors for Treatment BioCryst of Psoriasis, Ankylosing $244,479.25 Pharmceuticals, Inc. Spondylitis, & Multiple Sclerosis Disease Diagnostic Panel Diatherix Laboratories, Development Utilizing the $244,479.25 Inc. TEM-PCR Method Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 EGEN-001 in Platinum- EGEN INC $244,479.25 Resistant Ovarian Cancer EGEN, INC. EGEN TheraSilence $244,479.25 Development of an Apparatus iCubate, Inc $244,479.25 for Performing am-PCR Phase 1, Open-label Syudy Evaluting the Safety of PNP Therapeutics Inc $244,479.25 Escalating Doses of Ad/PNP- F-araAMP SER-201 for the treatment of Serina Therapeutics, Inc $244,479.25 colorectal and ovarian cancer Development of an Vaxin Inc.
    [Show full text]
  • Annual Report 2020
    ANNUAL REPORT 2020 Caring for People’s Health as a Trusted Partner 2020 A Year like none before Peter Goldschmidt CEO Dear Investors, dear Partners, 2020 was for each of us a demanding year. Like all of you, we at STADA had to deal with new challenges and to adapt to a new situation in our jobs as well as at home with our family. I would like to express my gratitude to all employees worldwide. You have made an extraordinary contribution to our society through your tireless efforts. We can be proud of the strong crisis resilience STADA has shown despite challeng- ing market conditions during the pandemic. The company has proven itself to be a growth leader and go-to-partner in Consumer Healthcare and Generics, with a rapidly expanding Specialty Pharma presence in areas such as Parkinson’s and biosimilars. I’m particularly gratified by how our diverse global team has come through the crisis true to our Purpose of “Caring for People’s Health as a Trusted Partner”. Across the organization, people have pulled together, even if they have been physically distant; this close collaboration across continents truly embodies our value One STADA. Keep Supplying Medicines We care for people’s health as a trusted partner by being able to keep supplying medicines, even during lockdowns. Our 6,000 production staff did an outstanding job in these difficult times. STADA provides a broad portfolio from supplements that enable people to stay healthy and support their immune systems through to essential treatments for diseases in nearly every therapeutic area, such as cancer, heart, central nervous system, gastrointestinal and pain relief.
    [Show full text]
  • BIO Digital Sample Attendee List As of June 6, 2021 TITLE COMPANY
    BIO Digital Sample Attendee List as of June 6, 2021 TITLE COMPANY COUNTRY Chief Strategy Officer (Former) -- Brand Marketing Manager 1nHealth Inc Director of Partnerships 1nHealth Inc Manager 1ST Biotherapeutics, Inc. Korea, Republic of CEO 1ST Biotherapeutics, Inc. Korea, Republic of Senior Scientist 1ST Biotherapeutics, Inc. Korea, Republic of CEO 20Med Therapeutics Netherlands Senior Director 360 Live Media Sr. Marketing Manager 360 Live Media Vice President 360 Live Media Experience Design Manager 360 Live Media Executive Vice President, Business Development 360biolabs Australia Executive Director 3DforScience - Visuals for Bio & Health Spain Business Development Manager 3P BIOPHARMACEUTICALS Spain Senior Head of Business Development 3P BIOPHARMACEUTICALS Spain BD Manager 3S Bio China Head of BD 3SBIO, INC China CSO 3Z Pharmaceuticals Iceland Chief Scientific Officer 490 Biotech Inc. Managing Partner 4BIO Capital United Kingdom Investment Director 4BIO Capital United Kingdom Chief Business Officer 4d Pharma Plc United Kingdom Corporate Development 4d Pharma Plc United Kingdom Business Development and Licensing Manager 4P-Pharma France Director Operations and Business Development 4sc AG Germany Founder and CEO 501 Ventures, LLC COO and CBO 89bio, Inc. SVP, Corporate Development & Operations 9 Meters Biopharma, Inc. President & CEO 9 Meters Biopharma, Inc. Business Development Manager A. Menarini I.F.R. Germany Corporate Licensing Associate A. Menarini I.F.R. Italy Corporate Director BD&L Specialty Discovery and Development A. Menarini I.F.R. Italy President A4I/MEMOTEXT Canada Director of Operations - SEA Change AAAS Founder & CEO Aagami, Inc. Co-Founder and CEO A-Alpha Bio CEO AAVogen CSO Abalone Bio CEO Abalone Bio Inc Chairman Abarceo Pharma AB Sweden CEO Abarceo Pharma AB Sweden CEO Abartys Health, LLC CBO Abbisko Therapeutics Co.
    [Show full text]
  • Immunogenicity and Safety of Fractional Doses of Yellow
    medRxiv preprint doi: https://doi.org/10.1101/2020.08.18.20177527; this version posted August 21, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomized, 2 double-blind, non-inferiority trial 3 4 Aitana Juan-Giner1,*, Derick Kimathi2,3*, Kyra H. Grantz4,5,6, Mainga M. Hamaluba2, Patrick 5 Kazooba7, Patricia Njuguna2, Gamou Fall8, Moussa Dia8, Ndeye S. Bob8, Thomas P. 6 Monath9, Alan D. Barrett10, Joachim Hombach11, Edgar M. Mulogo12, Immaculate Ampeire13, 2 7 7 4,5 7 Henry K. Karanja , Dan Nyehangane , Juliet Mwanga-Amumpaire , Derek A.T. Cummings , 8 Philip Bejon2,3, George M. Warimwe2,3,#, Rebecca F. Grais1,#. 9 10 1 Epicentre, Paris, France 11 2 Kenya Medical Research Institute – Wellcome Trust Research Programme, Kilifi, Kenya 12 3 Centre for Tropical Medicine & Global Health, University of Oxford, UK 13 4 Department of Biology, University of Florida 14 5 Emerging Pathogens Institute, University of Florida 15 6 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health 16 7 Epicentre Mbarara Research Centre, Uganda 17 8 Institut Pasteur Dakar, Senegal 18 9 Crozet BioPharma LLC, Devens MA, USA 19 10 Sealy Institute for Vaccines Sciences and Department of Pathology, University of Texas 20 Medical Branch, USA 21 11 Immunization, Vaccines & Biologicals,
    [Show full text]